Section Arrow
CLNN.NASDAQ
- Clene
(Financial Status)
Quotes are at least 15-min delayed:2024/05/07 14:03 EDT
Last
 0.403
-0.0206 (-4.86%)
Day High 
0.43 
Prev. Close
0.4236 
1-M High
0.4397 
Volume 
204.31K 
Bid
0.4004
Ask
0.4066
Day Low
0.395 
Open
0.43 
1-M Low
0.304 
Market Cap 
54.40M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.39 
20-SMA 0.37 
50-SMA 0.4 
52-W High 1.09 
52-W Low 0.25 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.47/-0.28
Enterprise Value
66.46M
Balance Sheet
Book Value Per Share
0.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
654.00K
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CMNDClearmind Medicine1.41+0.24+20.51%-- 
JAGXJaguar Health0.2798-0.0372-11.74%-- 
DNAGinkgo Bioworks Holdings0.9821-0.006-0.61%-- 
FGENFibroGen1.3014+0.1414+12.19%-- 
LYRALyra Therapeutics0.427999-0.093501-17.93%-- 
Quotes are at least 15-min delayed:2024/05/07 14:03 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercializationof dietary supplements (Supplements).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.